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Abstract
Transient activation of the renin-angiotensin system (RAS) induces irreversible renal damage causing sustained elevation in
blood pressure (BP) in Cyp1a1-Ren2 transgenic rats. In our current study we hypothesized that activation of the AT1-
receptor (AT1R) leads to a T-cell response causing irreversible impairment of renal function and hypertension. Cyp1a1-Ren2
rats harbor a construct for activation of the RAS by indole-3-carbinol (I3C). Rats were fed a I3C diet between 4–8 weeks of
age to induce hypertension. Next, I3C was withdrawn and rats were followed-up for another 12 weeks. Additional groups
received losartan (20 mg/kg/day) or hydralazine (100 mg/kg/day) treatment between 4–8 weeks. Rats were placed for 24h
in metabolic cages before determining BP at week 8, 12 and 20. At these ages, subsets of animals were sacrificed and the
presence of kidney T-cell subpopulations was investigated by immunohistochemistry and molecular marker analysis. The
development of sustained hypertension was completely prevented by losartan, whereas hydralazine only caused a partial
decrease in BP. Markers of renal damage: KIM-1 and osteopontin were highly expressed in urine and kidney samples of I3C-
treated rats, even until 20 weeks of age. Additionally, renal expression of regulatory-T cells (Tregs) was highly increased in
I3C-treated rats, whereas the expression of T-helper 1 (Th1) cells demonstrated a strong decrease. Losartan prevented these
effects completely, whereas hydralazine was unable to affect these changes. In young Cyp1a1-Ren2 rats AT1R activation
leads to induction of an immune response, causing a shift from Th1-cells to Tregs, contributing to the development of
irreversible renal damage and hypertension.
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Introduction
One of the characteristics during structural remodeling of target
organs in hypertension is the presence of a distinct inflammatory
response [1]. Inflammation contributes to structural changes by
activation and/or inhibition of growth factors and proteases and
might be the predisposing factor for hypertension induced injury
[2]. The link between hypertension and inflammation has been
widely studied and several mechanisms and pathways are
proposed [3,4]. Angiotensin (Ang) II induces renal damage, both
in the presence and absence of hypertension [2]. In the past it has
been shown that Ang II when infused in animals at a dose below
the threshold of its vasoconstrictor effect (subpressor dose), BP rises
slowly and progressively over time [5,6]. Thus far, the exact cause
of this so-called late low-pressor response is still unclear.
Over the last two decades, Ang II has been recognized as an
important inducer of inflammation [2,7]. Binding of Ang II to the
angiotensin II type 1 receptor (AT1R) activates nuclear factor-
kappa B (NFkB) via upregulation of several proinflammatory
genes, thereby contributing to a local inflammatory response [2].
Furthermore, Ang II causes infiltration of inflammatory cells,
including macrophages and T-cells, in glomeruli and interstitium
[7–9]. The importance of a T-cell response in the pathophysiology
of hypertension induced injury has been established previously
[1,10,11]. Mice lacking T-cells develop less severe hypertension
than their wild type counterparts [7]. Some recent studies
demonstrate that a particular subpopulation of T cells, the
regulatory T cell (Treg), is able to prevent Ang II and
aldosterone-induced hypertension and injury [12,13]. However,
the exact mechanisms along which the different subtypes of T-cells
contribute to the development and progression of hypertension-
induced renal injury is incompletely understood. Nataraj and co-
workers presented one of the first studies that demonstrate a direct
action of Ang II on T lymphocytes via the AT1R [14]. The role of
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the AT1R in this process remains controversial. Whereas
numerous studies provide data that activation of the AT1R is
unfavorable, a recent study by Zhang et al [15] shows that the
AT1R expressed on T lymphocytes can limit target organ damage
in hypertension. Kidney injury molecule-1 (KIM-1) and osteo-
pontin (OPN) are recognized as regulators of T-cells and not
surprisingly they are also known as important renal injury markers
[16,17]. In patients AT1R blockade reduces renal damage and is
associated with less excretion of KIM-1 and OPN [18]. Therefore
we hypothesize that these markers might play an important role
via immune activation in angiotensin-induced renal pathogenesis.
In a recent study, we demonstrated that transient stimulation of
the renin-angiotensin system leads to sustained high BP in young
Cyp1a1-Ren2 transgenic rats due to the induction of irreversible
renal damage [19]. These rats harbour a genetic construct under
control of a Cyp1a1 promoter for the production of mouse renin 2
(mRen2) [20]. This promoter can be activated by adding indole-3-
carbinol (I3C) to the diet eventually leading to RAS-activation via
increased circulating prorenin- and renin-levels [21,22]. In the
current study we hypothesized that the induction of irreversible
renal damage in this model is mainly aggravated by an AT1R
activated immune response. For this reason we compared
hypertensive losartan- with hydralazine-treated Cyp1a1-Ren2
rats.
Animals, Materials and Methods
Ethics Statement
All animal experiments were performed in accordance with
guidelines issued in the ‘‘Guide for the Care and Use of
Laboratory Animals’’ (2010) and were approved by the institu-
tional Animal Care and Use Committee of Maastricht University.
Animals and Experimental Procedures
Transient malignant hypertension was induced in transgenic
young Cyp1a1-Ren2 rats by feeding the animals a diet containing
0.3% I3C (Sigma-Aldrich, St. Louis, Missouri, USA) between 4
and 8 weeks of age. As shown previously, BP remains elevated in
these rats up to 12 weeks after withdrawal of I3C and is associated
with irreversible renal damage accompanied by a moderate
inflammatory response [19].
First, we tested whether the elevation in BP and the
development of renal damage due to 4 weeks of RAS-stimulation
in Cyp1a1-Ren2 rats was prevented by AT1R-blockade via
losartan-treatment between 4–8 weeks of age. Losartan (MSD,
Oss, the Netherlands) was dissolved in PBS (GIBCO, Life
technologies, Carlsbad, CA, USA) and administered at a dose of
20 mg kg21 day21 via subcutaneously (s.c.) implanted osmotic
minipumps (MODEL 2004 Alzet, Durect Corporation, Cuper-
tino, CA, USA). The osmotic minipumps were primed 24 hours
prior to implantation under isoflurane anesthesia (1–4% Forane,
Abbott House, Berkshire, UK) and buprenorphine analgesia
(0.03 mg kg21 s.c. TEMGESIC).The dose of losartan was based
on previous studies by our group [23]. To demonstrate the
selectivity of AT1R activation, an additional group of RAS-
stimulated rats received hydralazine (Sigma-Aldrich) treatment
between 4–8 weeks of age. Hydralazine was administered via
drinking water at a dose of 100 mg kg21 day21. To check and
adapt treatment for proper dosing, rats were weighed and drinking
water with the appropriate dilution of hydralazine was freshly
prepared every two days. In addition, rats received s.c. an osmotic
minipump containing hydralazine at the highest possible dose
(3 mg kg21 day21) serving as a sham procedure and to boost
antihypertensive treatment with this agent. The effects of the
hydralazine treatment were compared to the age-matched control,
I3C-treated and I3C+losartan-treated group. At 8 weeks of age
animals were placed in metabolic cages to collect 24 hour urine
samples for the determination of albuminuria and the excretion of
renal injury markers. Additionally, at that age direct arterial blood
pressure was determined in the conscious state. For this purpose, a
polyethylene catheter was inserted into the right femoral artery
and shifted into the aorta under isoflurane anesthesia and
buprenorphine analgesia for more than 48 hours before measuring
mean arterial pressure (MAP).For each animal MAP was recorded
for approximately 1 hour. Further, renal vascular resistance (RVR)
was measured under pentobarbital anesthesia (50 mg kg21). A
transit time flow probe (VB series 0.5 nm, Transonic Systems Inc.,
Ithaca, New York, USA) was placed around the renal artery to
measure renal blood flow (RBF). After stabilization of hemody-
namics (.20 min), RBF and MAP were recorded simultaneously.
Renal vascular resistance (RVR) was calculated as MAP divided
by RBF and corrected for kidney weight. Afterwards, rats were
sacrificed by exsanguination via the abdominal aorta and the
kidneys were weighed and harvested for further molecular and
immuno-histochemical analysis.
In a second set of experiments we further evaluated the
underlying immune response and tested whether the 4 weeks of
AT1R-blockade, during the 4 weeks I3C-treatment with high
Figure 1. Experimental setup. Cyp1a1-Ren2 rats were treated from 4–8 weeks of age. The I3C-treated rats received 0.3% I3C via the diet, whereas
control rats received standard rat chow. Losartan was administered via s.c. implanted minipumps at a dose of 20 mg kg21 day21. Losartan and I3C-
treatment were stopped at 8 weeks of age and rats were followed-up until 20 weeks of age, i.e. 12 weeks after stopping the treatment-regiments.
Ctrl, Control; I3C, Indole-3-Carbinol.
doi:10.1371/journal.pone.0057815.g001
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circulating (pro-)renin and Ang II levels, was able to completely
prevent the development of hypertension and renal damage over
time. For this purpose we included 4 groups: control, control+lo-
sartan, I3C-treated and I3C-treated+losartan, and followed them
up until 20 weeks of age. At 8 weeks of age the osmotic minipumps
were carefully removed under isoflurane anesthesia and bupre-
norphine analgesia. At 8, 12 and 20 weeks of age animals were
placed in metabolic cages, direct arterial blood pressure and RVR
were determined and the rats were sacrificed and the organs were
processed for further analysis. Figure 1 illustrates the experimental
setup of this in vivo experiment.
Urinary Markers of Renal Injury
Albumin was measured in 24h urine samples using the
Beckman/Coulter Synchron LX 20 (Beckman Coulter, Inc., Brea,
California, USA). In addition, rat kidney injury panel 1 was
purchased from mesoscale diagnostics (MSD; K15162C-1, Meso
Scale Discovery, Gaithersburg, MD, USA). This assay detects
Table 1. Gene-specific primer sequences used for quantitative real-time PCR.
Gene Forward-primer 59-39 Reversed-primer 59-39
CD3 GCAACACCAGCATCAGGCAT CCCAAAGCCAGGAGCAGAGT
CD4 AGGACAGTGGCATCTGGAAC TGGGGTATCTGAAGGGTGAG
CD8 CCGGTCTGCCCATCATATAG GGGCAGTTCTCTTGTCTTGG
Cyclophilin A TTCCTCCTTTCACAGAATTATTCCA CCACCAGTGCCATTATGG
FoxP3 CCCAGGAAAGACAGCAACCTT CTGCTTGGCAGTGCTTGAGAA
GATA3 TTCCTGTGCGAACTGTCAGACCA CCTTTTTGCACTTTTTCGATTTGCTA
IL17 ATCAGGACGCGCAAACATG TGATCGCTGCTGCCTTCAC
KIM-1 CGGTGCCTGTGAGTAAATAGAT CTGGCCATGACACAAATAAGAC
Nephrin CGTGCTAAAGGCGAGTTCCA GGAGAGGATTACTTTAGGAGACACAAG
NGAL GACTCAACTCAGAACTTGATCCCT AGCTCTGTATCTGAGGGTAGCTGT
OPN TGAGACTGGCAGTGGTTTGC CCACTTTCACCGGGAGACA
PAI-1 GAGCCAGATTCATCATCAACG CTGCAATGAACATGCTGAGG
T-bet TCCACCCAGACTCCCCCAACA GGCTCACCGTCATTCACCTCCA
TGFb GCACCATCCATGACATGAAC GCTGAAGCAGTAGTTGGTATC
FoxP3, forkhead box P3; GATA3, GATA binding protein 3; IL17, Interleukin 17; KIM-1, kidney injury molecule 1; NGAL, neutrophil gelatinase associated lipocalin; OPN,
osteopontin; PAI-1, plasminogen activator inhibitor-1; T-bet, T-box expressed on T-cells; TGFb, transforming growth factor b.
doi:10.1371/journal.pone.0057815.t001
Figure 2. Effects of anti-hypertensive treatments on hemodynamics. At 8 weeks of age mean arterial blood pressure (MAP) (A) and renal
vascular resistance (RVR) (B) were significantly elevated in the I3C-treated group after renin-angiotensin system (RAS)- stimulation. Whereas losartan-
treatment was able to prevent the rise in MAP and RVR completely, hydralazine was also able to reduce them, yet MAP and RVR remained
significantly elevated. The n for each group is presented in the bars of figure A. I3C, Indole-3-Carbinol; KW, kidney weight; MAP, mean arterial pressure.
doi:10.1371/journal.pone.0057815.g002
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lipocalin-2 (NGAL), osteopontin, and kidney-injury-molecule
(KIM-1) in a sandwich immunoassay and uses a competitive
assay format to detect albumin. All reagents were provided with
the MSD kit. Each 96-well plate had 4-carbon electrodes in the
bottom of each well, each pre-coated with one of the 4-anti-kidney
injury markers antibodies of interest. The assay was performed
according to the manufacturers’ protocol [24]. Finally, albumin
and the renal injury markers were corrected for urinary creatinine,
determined on the Beckman/Coulter Synchron LX 20.
Gene Expression Analysis
Total RNA was isolated from a cross-section of the right kidney
by the TRIZOL-method (Invitrogen, Carlsbad, California, USA),
as previously described [19]. The purity and concentration of the
RNA was measured by means of the 260/280 ratio, and cDNA
synthesis was performed using 1000 ng RNA according to the
manufacturers’ protocol (iScript cDNA synthesis kit, Bio-Rad
Laboratories Inc., Hercules, California, USA). Gene expression
was analyzed by quantitative PCR on a Bio-Rad CFX96 system
(Bio-Rad Laboratories Inc) using the iQ SYBR-green supermix
(Biorad Laboratories Inc). All primers applied are presented in
Figure 3. Effects of anti-hypertensive treatments on urinary excretion of renal injury markers. Whereas losartan completely prevented
the development of albuminuria, hydralazine treatment was unable to induce any improvement (A). Furthermore, urinary excretion of KIM-1 and OPN
was fully inhibited by AT1-receptor blockade. Hydralazine only induced a slight decrease of these markers, yet, they remained significantly elevated
(B+C). The n for each group is presented in the bars of figure A. I3C, Indole-3-Carbinol; KIM-1, kidney injury molecule-1; OPN, osteopontin.
doi:10.1371/journal.pone.0057815.g003
Figure 4. Effects of anti-hypertensive treatments on gene expression of renal injury markers. Hydralazine treated rats expressed elevated
levels of the renal injury markers KIM-1, OPN and NGAL. When compared with the untreated RAS-stimulated rats, gene expression levels
demonstrated a decrease yet remained significantly elevated (A-C). This was in sharp contrast with losartan which caused a normalization of all
parameters. PAI-1 expression was unaltered whereas nephrin was significantly decreased by hydralazine when compared with untreated RAS-
stimulated rats (D+E). The n for each group is presented in the bars of figure A. I3C, Indole-3-Carbinol; KIM-1, Kidney injury molecule-1; NGAL, neutrophil
gelatinase associated lipocalin; PAI-1, plasminogen activator inhibitor-1.
doi:10.1371/journal.pone.0057815.g004
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Table 1. Results were normalized to the housekeeping gene
cyclophilin A and relative changes in expression levels were
subsequently calculated using the Bio-Rad CFX manager software
(Version 2.0, Biorad Laboratories Inc). Relative gene expression in
the control rats was normalized for each time-point to compare
them with the age-matched rats from the other three groups.
Figure 5. Effects of anti-hypertensive treatments on renal injury. Four weeks of RAS-stimulation caused a significant increase in renal
pathology, which is reflected by the GSI and TIS. AT1R-blockade completely prevented this, whereas hydralazine had no effect. The n for each group is
presented in the bars of the GSI. I3C, Indole-3-Carbinol; GSI, glomerulosclerosis index; TIS, tubulointerstitial score.
doi:10.1371/journal.pone.0057815.g005
Figure 6. Long-term effects of AT1-receptor blockade on hemodynamics. Mean arterial blood pressure (MAP) (A) and renal vascular
resistance (RVR) (B) were significantly elevated in the I3C-treated group after renin-angiotensin system (RAS)- stimulation between 4–8 weeks of age.
Losartan-treatment was able to prevent this completely. After stopping RAS-stimulation (after week 8) MAP and RVR decreased but remained
significantly elevated, even until 20 weeks of age. Losartan treatment was also able to prevent the development of this sustained high blood
pressure. The n for each group is presented in the bars of figure A. I3C, Indole-3-Carbinol; KW, kidney weight; MAP, mean arterial pressure.
doi:10.1371/journal.pone.0057815.g006
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Histochemisty and Immunostaining
PAS-D. The right kidney of each animal was excised, rinsed in
PBS (Invitrogen) and fixed in 4% formalin for 24 hours before
embedding in paraffin. Central cross-sections of 4 mm of the whole
kidney including medulla and cortex were deparaffinized and
stained for PAS-D. Briefly, the slides where incubated with
diastase (Merck; 1 g per 330 ml de-mineralized water) for 90
minutes. Next, slides were washed with de-mineralized water and
incubated in periodic acid (Merck) for 10 minutes, followed by a
second washing step with de-mineralized water. Then the slides
were subjected to 20 min incubation with Schiff reagent (Merck)
and washed with tap water. All slides were counterstained with
haematoxylin and rehydrated in increasing concentrations of
ethanol.
All sections were semi-quantitatively scored by a nephropathol-
ogist in a blinded manner as described previously [19]. Briefly,
Figure 7. Long-term effects of of AT1-receptor blockade on gene expression of renal injury markers. Gene expression of the renal injury
markers NGAL, KIM-1 and OPN was highly elevated after 4 weeks of RAS-stimulation (A–C). Stopping RAS-stimulation led to a decrease in expression,
nevertheless, the levels remained significantly elevated even until 20 weeks of age. At first, PAI-1 expression remained at control levels and was
increased at 12 and 20 weeks of age in the RAS-stimulated rats (D). Finally, the expression of nephrin demonstrated little to no differences (E). Only a
small decrease in expression was observed at 12 weeks of age in the RAS-stimulated rats. Losartan-treatment was able to prevent all of the effects on
the renal injury markers. In adult rats which do not develop sustained hypertension after 4 weeks of RAS-stimulation a normalization of all renal injury
markers occurs within 4 weeks after stopping the stimulation (data not shown). The n for each group is presented in the bars of figure A. I3C, Indole-3-
Carbinol; KIM-1, kidney injury molecule-1; NGAL, neutrophil gelatinase associated lipocalin; OPN, osteopontin; PAI-1, plasminogen activator inhibitor-1.
doi:10.1371/journal.pone.0057815.g007
Figure 8. Expression of glomerular WT-1. RAS-stimulated rats, with or without AT1-receptor blockade, did not demonstrate differences in WT-1
positive cells when compared with normotensive controls. The n for each group is presented in the bars of the figure. DIA, diameter; I3C, Indole-3-
Carbinol; WT-1, Wilms’ tumor 1.
doi:10.1371/journal.pone.0057815.g008
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Figure 9. Long-term effects of AT1-receptor blockade on urinary excretion of renal injury markers. RAS-stimulated rats developed
sustained albuminuria (A). The excretion of urinary KIM-1 and OPN demonstrated the same pattern (B+C). The excretion of all renal injury markers was
completely prevented by losartan. The n for each group is presented in the bars of figure A. I3C, Indole-3-Carbinol; KIM-1, kidney injury molecule-1;
OPN, osteopontin.
doi:10.1371/journal.pone.0057815.g009
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Figure 10. Long-term effects of AT1-receptor blockade on renal injury. Four weeks of RAS-stimulation induced irreversible renal damage.
Despite high levels of circulating RAS-components, supplementary AT1R-blockade was able to completely prevent the development of renal
pathology over time. The n for each group is presented in the bars of the GSI. GSI, glomerulosclerosis index; I3C, Indole-3-Carbinol; TIS, tubulointerstitial
score.
doi:10.1371/journal.pone.0057815.g010
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renal scarring of all glomeruli was scored on an arbitrary scale
from 0 to 4. Grade 0 indicated no glomerulosclerosis, grade
1,25% of sclerosis, grade 2 25–50% of sclerosis, grade 3 50–75%
of sclerosis and grade 4.75% of sclerosis per glomerulus.
Hereafter, the individual glomerulosclerosis index (GSI) was
calculated for each rat. Furthermore, 10 images of each kidney
section (1006magnification) were analyzed for tubular atrophy,
interstitial fibrosis and total renal inflammation according to the
Banff classification. Each parameter was graded a score of 0 to 3,
where 0 meant no changes in pathology, grade 1,25% of change,
grade 2 a 25–50% difference and grade 3.50% of affected tissue.
From these data the tubulointerstitial score (TIS) was calculated.
WT-1. To analyze the glomerular filtration barrier and gain
more insight in the glomerular structural alterations a Wilms’
tumor 1 (WT-1) staining was performed on paraffin embedded
tissue. First, slides were subjected to ‘Target Retrieval Solution’
(DAKO Denmark A/S, Glostrup, Denmark) at 96uC for 10
minutes. Next, peroxidase activity was blocked by Envision flex
peroxidase block (DAKO) for 5 minutes. Hereafter, the tissues
were put on WT-1 ready-to-use (DAKO) for 20 minutes, Envision
Flex HRP (DAKO) for 20 minutes and Diaminobenzidine (DAB)
(DAKO) for 10 minutes. This final step was blocked by the
addition of tap water. Finally, the tissues were counterstained with
haematoxylin and dehydrated in increasing concentrations of
ethanol. Analysis of WT-1 was done by light microscopy at a
magnification of 2006. For each subject approximately 20
randomly selected glomeruli were analyzed throughout the entire
cortex. WT-1 positive cells were counted and corrected for
glomerular diameter as determined by a computerized morpho-
metric system (Leica Qwin 3.1). The average data of all glomeruli
per subject were then used in the analysis.
CD3. A CD3 staining was performed to determine T-cell
infiltration in the kidney. First, slides were incubated for 30
minutes in 0.3% peroxide in PBS to block endogenous peroxidase
activity. Next, antigen retrieval was performed by boiling the slides
in a Tris EDTA buffer (1.2 g/L Tris and 0.37 g/L EDTA, pH 9)
for 10 minutes. Primary antibody (mouse-a-human CD3 (DAKO),
1:200 in PBS with 1% BSA) was incubated overnight at 4uC.
Hereafter, slides were incubated for 30 minutes with secondary
antibody (rabbit-a-mouse peroxydase conjugated, 1:1000 in PBS,
DAKO). Subsequently, Envision anti-rabbit incubation for 30
minutes and DAB (DAKO) was used to obtain staining of the T-
cells. Finally, the tissues were counterstained with haematoxylin
and dehydrated in increasing concentrations of ethanol. Analysis
of CD3 was done by light microscopy at a magnification of 200x
by means of 10 photos per subject throughout the entire cortex.
Brown staining was measured as percentage of total tissue area
using a computerized morphometric system (Leica Qwin 3.1).
Statistical Analysis
Data are expressed as mean 6 S.E.M. and were analyzed by
one-way or 2-way ANOVA with post-hoc Bonferroni correction
when appropriate, followed by unpaired Student’s t test. Differ-
ences were considered statistically significant if p-values ,0.05 (*
p,0.05, { p,0.01 and { p,0.001).
Results
Effects of Anti-hypertensive Treatments
Hemodynamics. Four weeks of RAS activation in the I3C-
treated rats led to a significant increase in mean arterial pressure
(MAP). Losartan-treatment between 4–8 weeks of age was able to
block the rise in MAP. In addition, the RAS-independent lowering
of blood pressure by hydralazine demonstrated a significant, yet
only a partial reduction in MAP. RVR was also partially
decreased. (Fig. 2A+B).
Markers of renal damage. RAS-stimulated rats developed
albuminuria (Fig. 3A). Furthermore, the excretion of urinary
KIM-1 and OPN was significantly increased (Fig. 3B+C) and
followed a similar pattern as renal gene expression (Fig. 4).
Losartan-treatment fully prevented the increase in expression of
these renal injury markers and inhibited the excretion of them as
well as of albumin. In contrast, in hydralazine treated-rats renal
expression and urinary excretion of KIM-1, NGAL and albumin-
uria were in the same range as non-treated RAS-stimulated rats,
whereas excretion of OPN was slightly decreased. These data are
supported by analysis of PAS-D stained kidney slides and
determination of renal pathology by means of GSI and TIS
(Fig. 5). In short, whereas losartan completely prevents the
development of an increased GSI and TIS, hydralazine is unable
to improve renal pathology.
Long-term Effects with and without AT1R-blockade
Hemodynamics. After withdrawal of I3C from the diet,
MAP decreased in the I3C-treated rats but remained highly
elevated at 12 weeks of age. Even at 20 weeks of age, i.e. 12 weeks
after stopping RAS-stimulation, MAP remained significantly
higher when compared with the control rats. RVR demonstrated
the same pattern. Four weeks of AT1R-blockade was able to
completely prevent these effects. (Fig. 6A+B).
Markers of renal damage. Stopping RAS-stimulation led to
a decrease in expression of the renal injury markers KIM-1, OPN
and NGAL. Nevertheless, the levels remained significantly
elevated even until 20 weeks of age (Fig. 7A–C). Whereas the
increase of these markers was present immediately at 8 weeks of
age, PAI-1 expression remained at control levels at first. Later on,
PAI-1 demonstrated increased expression levels in the RAS-
stimulated rats at 12 and 20 weeks of age (Fig. 7D). Finally, the
expression of nephrin demonstrated little to no differences
(Fig. 7E). Only a small decrease in expression was observed at
12 weeks of age in the RAS-stimulated rats. Further evaluation of
the glomerular filtration barrier was done by immunohistochem-
ical analysis of WT-1 expression at 8 weeks of age, i.e. when
albuminuria was most prominent. Again no differences were
observed (Fig. 8).
In figure 9 the urinary excretion levels of KIM-1 and OPN are
presented and demonstrate similar patterns as observed for renal
gene expression. In addition, albuminuria remained significantly
present even 12 weeks after stopping RAS-stimulation (Fig. 9A).
Losartan fully blocked all these effects, which is again supported by
Figure 11. Long-term effects of AT1-receptor blockade on renal gene expression of T-cell markers. CD3 expression increases gradually
and reaches statistical significance at 20 weeks of age in the RAS-stimulated rats. (A). FoxP3 expression demonstrated an elevation at 8 weeks of age
in the RAS-stimulated rats, this increase became even more pronounced 4 weeks later and was still present, yet not significant, at 20 weeks of age (B).
RAS-stimulated rats demonstrated a significant decrease in T-bet expression. This decrease was still present 4 weeks later, but disappeared at 20
weeks of age (C). Losartan treatment completely prevented the effects on CD3, FoxP3 and T-bet expression. GATA3, was only increased in the RAS-
stimulated rats which received losartan treatment. After stopping stimulation and treatment GATA3 expression returned back to normal (D). Finally,
no differences were observed in renal IL17 expression (E). The n for each group is presented in the bars of figure A. FoxP3, forkhead box P3; GATA3,
GATA binding protein 3; I3C, indole-3-carbinol; IL, interleukin; T-bet, T-box expressed on T-cells; Wks, weeks.
doi:10.1371/journal.pone.0057815.g011
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the absence of renal pathology when compared with untreated
age-matched RAS-stimulated rats (Fig. 10).
T-cell response. Renal gene expression of the general T-cell
marker CD3 increased gradually and reached statistical signifi-
cance at 20 weeks of age in the RAS-stimulated rats. At 8 weeks of
age losartan-treatment in this group caused a decrease in CD3
expression and completely prevented the rise over time (Fig. 11A).
This same pattern was confirmed by immunohistochemical
staining (Fig 12). Additionally, Forkhead box protein 3 (FoxP3)
expression, a marker of Tregs, was significantly elevated at 8 and
12 weeks but not anymore at 20 weeks of age. Treg function can
be addressed by analysis of transforming growth factor b (TGFb)
expression. In RAS-stimulated rats the increase in Tregs did not
result in an increased TGFb expression (8 weeks: 1.1360.08
versus 1.0060.03 in the control group; and 12 weeks: 1.0060.05
versus 1.0060.08). Besides, RAS-stimulated rats demonstrated a
significant decrease in T-box expressed on T-cells (T-bet)
expression, a marker of T helper (Th) 1-cells. This decrease was
still present 4 weeks later, but disappeared at 20 weeks of age.
Losartan treatment completely prevented the effects on Treg- and
T-bet expression (Fig. 11B+C). Finally, a marker of Th2-cells,
GATA binding protein 3 (GATA3), was only increased in the
RAS-stimulated rats which received losartan treatment. After
stopping stimulation and treatment GATA3 expression returned
back to normal (Fig. 11D). Finally, no differences were observed in
renal interleukin (IL)17 expression (Fig. 11E). Despite the decrease
in BP, renal expression of CD3, FoxP3 and T-bet was completely
unaffected by hydralazine treatment when compared with
untreated RAS-stimulated rats (Fig 13).
Figure 12. T-cell infiltration as determined by CD3 immunohistochemistry. CD3 staining of kidneys revealed a time-dependent increase of
T-cells after stopping the 4 weeks of RAS-stimulation in I3C-treated animals. Losartan completely prevented this rise in T-cells. These results are in line
with the data on renal gene expression. The n for each group is presented in the bars of the GSI. GSI, glomerulosclerosis index; I3C, Indole-3-Carbinol;
TIS, tubulointerstitial score.
doi:10.1371/journal.pone.0057815.g012
Figure 13. Effects of anti-hypertensive treatments on renal gene expression of T-cell markers. CD3, FoxP3 and T-bet expression were
unaffected by hydralazine treatment (A-C) when compared with untreated RAS-stimulated rats. As also seen for losartan, hydralazine increased
GATA3 expression (D). The n for each group is presented in the bars of figure A. FoxP3, forkhead box P3; GATA3, GATA binding protein 3; I3C, indole-3-
carbinol; T-bet, T-box expressed on T-cells; Wks, weeks.
doi:10.1371/journal.pone.0057815.g013
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Discussion
The new findings of this study are that sustained hypertension
induced in young Cyp1a1-Ren2 rats by transient RAS-stimulation
is associated with (1) increased renal expression and urinary
excretion of the T-cell inducers and renal injury markers KIM-1
and OPN; (2) a specific T-cell response, consisting of an
upregulation of Tregs and downregulation of Th1 cells, suggesting
a shift in T-cell subpopulations, is present in the kidney and may
be the underlying inducer of the irreversible renal damage in this
model; and (3) the induction of the immune response is AT1R-
mediated and might be to some extent even blood pressure
independent.
Renal Injury and Inflammation
Transient activation of the RAS in the transgenic Cyp1a1-Ren2
rat induces sustained high blood pressure and renal remodeling
and damage [19,25]. We hypothesized that the renal phenotype
might be caused by a persistent inflammatory response. We
therefore evaluated gene expression levels of renal glomerular and
tubular injury markers. Recently, KIM-1, OPN and NGAL have
been proposed as predictive biomarkers of chronic kidney disease
[24]. Gene expression of all three markers was highly elevated in
the kidneys of the RAS-stimulated rats and remained increased.
Whereas KIM-1 in the kidney is mainly expressed in injured
tubules [17], OPN is expressed in different structures of the
kidney. NGAL is expressed by renal epithelial cells, but also
abundantly by immune cells like neutrophils and macrophages
[26]. KIM-1 and OPN are also highly expressed in several cell-
types of the immune system and play a crucial role in the
regulation of local inflammation. KIM-1 is expressed on both Th1
and Th2 cells and is involved in the regulation or promotion of T-
cell activation [27]. OPN has pro- and anti-inflammatory effects
and facilitates macrophage and T-cell recruitment to damaged
tissue [28]. The elevated expression of these markers is consistent
with the observation that the kidneys of RAS-stimulated rats suffer
extensive damage accompanied by a local inflammatory response.
The observation that KIM-1 and OPN protein excretion was
highly elevated in the urine is strongly indicative for a loss of
tubular function in the kidneys of these animals. This finding is
enforced by the increased proteinuria/albuminuria observed in
this model [19,29]. PAI-1, a protease inhibitor closely related to
the progression of glomerulosclerosis [30], increased over time in
the RAS-stimulated rats. Possibly, PAI-1 is also involved in
maintaining renal damage by attracting immune cells [31]. Studies
in Cyp1a1-Ren2 rats indeed show increased influx of macrophag-
es [19,32]. Renal gene expression of nephrin was almost unaltered
indicating that the glomerular filtration barrier was nearly
unaffected in these rats. This finding was supported by the fact
that the amount of WT-1 positive cells remained the same in the
glomeruli of all groups. WT-1 is expressed by glomerular
podocytes and when impaired it can result in malfunctioning of
the filtration barrier via a decreased transcription of nephrin [33].
Despite an unaffected barrier the RAS-stimulated rats demon-
strated high albuminuria. Cyp1a1-Ren2 rats may have a complete
pressure depend albuminuria without directly affecting the barrier
itself. It is known from literature that despite the elevated BP and
albuminuria glomerular filtration rate is unaffected in these rats
[25,34].
AT1R-blockade has proven to be very effective against the BP
increase in Cyp1a1-Ren2 rats [29,35,36]. This was also seen in the
present study where BP and RVR completely returned to control
values despite an elevation in plasma (pro-)renin and AngII-levels
[35,36]. More importantly, after transient RAS stimulation the
losartan-treated rats remained normotensive, suggesting that no
significant structural changes and/or damage occurred that would
induce a hypertensive phenotype later in life. Hence, the
importance of (pro-)renin receptor-((P)RR) and/or AT2R-activa-
tion in contributing to the renal phenotype is probably neglectable.
Additionally, AT1R-blockade completely prevented the expression
and excretion of renal injury markers and subsequently no renal
damage was observed. Whereas RAS-independent BP lowering by
hydralazine was able to reduce the elevation of BP in RAS-
stimulated rats, KIM-1, OPN, albuminuria and renal pathology
were evidently present and almost unaffected. The inability of
hydralazine to decrease renal injury was also seen in a study by
Shao et al. where Ang II stimulated animals showed a similar
renal injury score as observed in the hydralazine-treated animals
with Ang II [11]. This is a strong indication that AT1R-activation
is the main contributor to the irreversible renal injury we observed
in young Cyp1a1-Ren2 transgenic rats after transient RAS-
stimulation [19]. Yet, the underlying mechanisms of this are
insufficiently understood and are still subjected to intense research.
Upregulation of local RAS components may be of high
importance in the pathology of renal damage in these rats, an
effect that can be blocked by addition of an ARB [37].
Presence of an Underlying T-cell Mediated Immune
Response
As mentioned before, the upregulation of renal KIM-1 and
OPN expression could be explained by the influx of immune cells,
such as macrophages and lymphocytes, in the kidney. AT1R-
activation by Ang II is an established key factor in the initiation of
the immune response and causes an upregulation of several
transcription factors, chemokines and cytokines, such as NFkB,
TNFa and ICAM-1. On their turn, these factors attract infiltrating
immune cells and enhance the immune response, which then
increases the local expression again of KIM-1, OPN and NGAL
[7,9]. Additionally, part of the Ang II effects on immunity is
caused by direct action on adaptive immune cells [7]. T-cells
express AT1R and may play a role in regulating blood pressure
and target organ damage [15]. Zhang et al. demonstrate that
AT1R on T-cells limit hypertensive injury to end-organs. Hence, a
depressed T cell function is a characteristic of an adaptive immune
response underlying hypertension. This concept has been
proposed before by studies that put immune perturbation forward
among which a depressed T cell function was suggested [38,39].
An imbalance of T-cell subpopulations might be the root to
pathological renal damage [11]. The entire T-cell population
consists of a variety of subpopulations including Th1, 2 and 17
cells and Tregs, all with different functions and activation
pathways. Injury resolution is an established function of Tregs.
These cells typically express the transcription factor FoxP3 and
normally participate in the amelioration of inflammatory-induced
injury [40]. Recent studies demonstrate increases of Tregs in
various organs, such as the heart and vessels, in a variety of
hypertensive models. They all show that these cells play an
important role in the reduction of high blood pressure and end-
organ damage [1,12,13,41,42]. Th17 cells can play a role in
immunity against extracellular bacteria and fungi, as well as in
autoimmune reactions and diseases [43]. It was reported that IL17
produced by Th17 cells plays a critical role in maintenance of
AngII-induced hypertension [44]. This study however demon-
strates no difference in renal IL-17 expression, which may exclude
the involvement of Th17 cells in the renal pathology observed in
our model.
Nevertheless, T-cells might still be the causative factor in the
irreversible renal damage observed in the Cyp1a1-Ren2 model.
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Renal CD3 expression was unaltered upon RAS-stimulation,
however the expression increased over time indicating that there is
a persistent influx of T-cells. Furthermore, the expression patterns
indicate that Tregs are highly present whereas Th1 cells seem to
be repressed. A possible explanation might be that there is a shift
from Th1 cells to Tregs as a response to the hypertension stimulus.
The Tregs are probably attracted to protect and ameliorate renal
pathology by mechanisms reviewed by Bromly et al [45].
Unfortunately, they are unable to prevent the development of
irreversible renal damage which might indicate a Treg dysfunction
[46]. The absence of differences in TGFb expression, a key
regulator of the signaling pathways that initiate and maintain
Foxp3 expression, supports this idea [47]. Whatever the mecha-
nism, losartan-treatment completely prevented the alterations in
expression of T-cell subpopulations, whereas hydralazine was
unable to do so. It has been shown before that AT1R blockade
restores T-cell population subsets back to normal [11]. This was
not the result of blood pressure lowering, since hydralazine did not
induce changes to the Th subsets [11]. This is in contrast to a
study in which hydralazine was able to impair T-cell activation in
Ang II stimulated mice [48]. It is difficult to pinpoint the cause-
effect relationship between hypertension and inflammation, but
the importance of this interplay and the involvement of the AT1R
is unquestionably apparent.
In the past Lever and co-workers have intensively studied the
role of low-pressor dose infusion of Ang II and its possibility to
induce hypertension later in life [6,49]. Over the years the
involvement of vascular hypertrophy has been demonstrated,
however, a conclusive mechanism has not been found for this
interesting phenomenon. This study may provide an explanation
by demonstrating the importance of AT1R activation in the
induction of an underlying immune response. AT1R activation
occurs already with low levels of circulating Ang II, inducing
inflammatory reactions which could slowly result in remodeling
processes that ultimately lead to hypertension. Of course more
research would be needed to strengthen this hypothesis.
This study comes with some limitations. First, the analysis of T-
cell subsets can be done by fluorescence-activated cell sorting
(FACS). In addition, the data on IL17 expression is only indirect
evidence that the Th17 subpopulation does not contribute to the
phenotype we observe. Providing FACS data of the different T-cell
subsets, including Th17 cells, would possibly strengthen the
outcome of the present study. Yet, due to technical reasons these
data were not acquired during the experiments. Furthermore, we
state that there might be a Treg dysfunction in our model.
Unfortunately, functional studies to check whether this is actually
the case have not been performed and are unavailable in this
study. Studies with FACS analyses and functionality tests are
subjected in our current research. Despite these limitations, we
believe that a significant amount of data provides evidence that T-
cell aberration plays an important role in the development of renal
damage in our Cyp1a1-Ren2 rat model.
Perspectives
The clinical significance of our experimental observations is that
they underscore the potential importance of inflammatory
responses in the kidney to an elevation in BP at young age. This
study gives a hint that at early age the induction of renal
inflammation can introduce a persistent adaptive immune
response which may cause pathological changes to the kidney
that eventually contribute to the development of established
hypertension. As seen in the present study the immune response
was mainly provoked by AT1R-activation which might indicate
that RAS blockers are essential in the treatment of high BP.
Potential biomarkers for renal injury and/or renal inflammation,
such as KIM-1 and OPN, should be taken into account when
considering antihypertensive treatment. The focus of current
treatment regiment is based upon treating patients with blood
pressures above prehypertension, whereas low circulating levels of
Ang II without vasoconstrictive effects can already lead to
hypertension later in life. Furthermore, a modest increase in BP
already induces T cell activation [48], possibly by mechanisms
recently proposed by Harrison and co-workers [4] and via direct
activation of AT1R on T-cells [15]. It would be of great interest to
investigate in prehypertensive patients to which degree early renal
inflammatory mechanisms are correlated to the proposed
biomarkers and how they contribute to the transition to
established hypertension.
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